We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
New UK fund cornerstoned by £50 million investment from the British Business Bank, through its Enterprise Capital Funds (ECF) programme Epidarex Capital III UK LP will invest in new life science comp... Combines Best-in-Class Bone Repair with Intraoperative Ease-of-Use for Spine and Trauma Bone Grafting Applications Aberdeen, UK, 17 June 2020 – SIRAKOSS Ltd, a developer of nanosynthetic bone graft ...
EPIDAREX CAPITAL CLOSES NEW £102 MILLION UK VENTURE FUND TO BUILD SUCCESSFUL LIFE SCIENCE COMPANIES
SIRAKOSS Receives U.S. FDA 510(k) Clearance for Osteo3 ZP Putty to Catalyse Rapid and Complete Bone Regeneration